Gujarat Themis Biosyn Ltd reports inter‑se transfer of 2.29% stake to promoter relative Sachin D. Patel

What Gujarat Themis Biosyn Ltd announced

Gujarat Themis Biosyn Ltd (the "Company") disclosed that on 30 June 2026 an inter‑se transfer of 24,97,190 equity shares was completed. The shares were transferred from Themis Medicare Limited to Sachin D. Patel, an immediate relative of the promoters. The transaction represents 2.29 % of the diluted share capital of the Company and was executed at Rs 400.45 per share. The filing, made under SEBI’s Regulation 10(6), was submitted to both the BSE and NSE on 1 July 2026.

Details of the inter‑se transfer

• Acquirer: Sachin D. Patel (promoter relative)\
• Seller/Transferor: Themis Medicare Limited (promoter group entity)\
• Number of shares transferred: 24,97,190 (rounded to 24.97 lakh)\
• Percentage of diluted capital: 2.29 %\
• Price per share: Rs 400.45\
• Total consideration (approx.): Rs 1,000 crore (24,97,190 × Rs 400.45)\
• Date of acquisition: 30 June 2026\
• Date of prior intimation (Reg 10(5) filing): 23 June 2026\
• Date of Regulation 10(6) filing: 1 July 2026 (timestamp 06:17:08 UTC)\

The transfer is classified as an inter‑se transfer among promoters and promoter group, meaning the shares moved within entities that are already part of the controlling family. No cash proceeds are expected to flow to the public shareholding base.

Regulatory framework and exemptions

The filing references two key provisions of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011:

1. Regulation 10(6) – Requires any acquisition that relies on an exemption to be reported to the stock exchanges. The Company complied by filing the disclosure on 1 July 2026.
2. Regulation 10(1)(a)(i) – Provides an exemption from the mandatory open‑offer requirement when the acquirer is an immediate relative of the promoters. Because Patel falls under this category, the transaction does not trigger an open‑offer to other shareholders.

The filing also confirms that the earlier Regulation 10(5) disclosure (the four‑day pre‑transaction notice) was made on 23 June 2026, satisfying the statutory timeline.

Shareholding impact

The transfer increased Patel’s direct holding from a nominal 10 shares to 24,97,200 shares, consolidating promoter control. Themis Medicare’s stake fell by 2.48 % of the total share capital, but it remains the largest single shareholder with 20.90 %.

Key facts at a glance

Why this matters for investors

The transaction is intra‑group and does not dilute the public shareholding base. However, it does increase promoter concentration by raising Patel’s stake to over 2 % and reducing Themis Medicare’s holding. Because the acquisition is exempt from a mandatory open‑offer, other shareholders will not receive any cash consideration or opportunity to sell. The price of Rs 400.45 per share is disclosed, but the filing does not indicate whether this price reflects market valuation or an internal agreement. Investors should note that the move strengthens the promoter group’s voting power, which could influence future strategic decisions, board composition, or related‑party transactions.

Conclusion

Gujarat Themis Biosyn Ltd has complied with SEBI’s takeover regulations by reporting an inter‑se transfer of 24.97 lakh shares from Themis Medicare Ltd to promoter relative Sachin D. Patel. The transfer, valued at Rs 400.45 per share, represents 2.29 % of the diluted share capital and is exempt from an open‑offer. While the public shareholding remains unchanged, promoter control is marginally consolidated. All required disclosures under Regulations 10(5) and 10(6) have been filed, and no further regulatory approvals are pending for this specific transaction.